Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients

Fifty seven episodes of severe cytomegalovirus (CMV) infection were treated with iv foscarnet in 13 bone marrow and 33 renal graft recipients. The ranges of the daily dose, duration, average steady state level and total dose were 23–268 mg/kg, 2–46 days, 42–400 mg/l and 2–399 g, respectively. Advers...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1986-03, Vol.17 (3), p.373-387
Main Authors: Ringdén, O., Lönnqvist, B., Paulin, T., Ahlmén, J., Klintmalm, G., Wahren, B., Lernestedt, J.-O.
Format: Article
Language:English
Subjects:
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - adverse effects
Antiviral Agents - metabolism
Antiviral Agents - therapeutic use
Biological and medical sciences
Bone Marrow Transplantation
Cytomegalovirus Infections - drug therapy
Cytomegalovirus Infections - etiology
Electrolytes - blood
Female
Foscarnet
Humans
Kidney Transplantation
Kinetics
Liver Function Tests
Male
Medical sciences
Middle Aged
Organophosphorus Compounds - therapeutic use
Pharmacology. Drug treatments
Phosphonoacetic Acid - adverse effects
Phosphonoacetic Acid - analogs & derivatives
Phosphonoacetic Acid - metabolism
Phosphonoacetic Acid - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty seven episodes of severe cytomegalovirus (CMV) infection were treated with iv foscarnet in 13 bone marrow and 33 renal graft recipients. The ranges of the daily dose, duration, average steady state level and total dose were 23–268 mg/kg, 2–46 days, 42–400 mg/l and 2–399 g, respectively. Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only. Increased liver enzymes, hallucinations and tremor were seen in one uraemic patient and coincided with foscarnet plasma concentrations above 400 mg/l. Among 25 patients evaluated for clinical efficacy, 12 died. Improvements, such as eradication of CMV (8/14 assessable patients), resolution of fever (11/22), and improved laboratory values (13/23) were noted in 17/24 (70%). Controlled trials are warranted on the basis of this study.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/17.3.373